EARSのチャート
EARSの企業情報
| symbol | EARS |
|---|---|
| 会社名 | Auris Medical Holding AG （オ―リス・メディカル・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus both in Phase 3 of clinical trials as well as AM-102 indicated for tinnitus undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland Ireland and the United States. オ―リス・メディカル・ホ―ルディングスは、スイスのバイオ医薬品会社。内耳障害の治療のため、新規製品の開発に注力する。製品候補「AM-101」は、第3相臨床段階にあり、急性内耳耳鳴りの治療のために開発中である。また、急性内耳性難聴のために「AM-111」を開発する。 Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.' |
| 本社所在地 | Bahnhofstrasse 21 Zug 6300 CHE |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +41 41-729-7194 |
| 設立年月日 | 1998年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | 24人 |
| url | www.aurismedical.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ears |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.46192 |
| 終値（lastsale） | 0.65 |
| 時価総額（marketcap） | 3976302.2 |
| 時価総額 | 時価総額（百万ドル） 3.66432 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2.85392 |
| 当期純利益 | 当期純利益（百万ドル） -15.55217 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Auris Medical Holding AG revenues was not reported. Net loss decreased 65% to SF4.8M. Lower net loss reflects Research and development decrease of 54% to SF5M (expense) Revaluation gain from derivative financi increase from SF1.8M to SF3.9M (income) Foreign currency exchange losses net decrease of 93% to SF66K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SF3.37 to -SF0.81. |
EARSのテクニカル分析
EARSのニュース
Tinnitus Drug Pipeline Market 2021 by Product Type, Application, Region and Key Players - AudioCure Pharma GmbH , Auris Medical Holding AG, Autifony Therapeutics Ltd, Decibel Therapeutics Ltd 2021/06/22 10:09:00 OpenPR
The Tinnitus Drug Pipeline Market research report is prepared by an in-depth analysis of the present market status and historical data of the Medical Devices industry. The report offers valuable insights by studying the significant market segments such as top
Auris Medical Holding (EARS) Presents At LD Micro Invitational XI Conference - Slideshow 2021/06/11 19:08:10 Seeking Alpha
Auris Medical Holding to Present at LD Micro Invitational XI Conference 2021/05/28 00:00:00 BioSpace
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference
Tinnitus Drug Pipeline Market 2021 by Product Type, Application, Region and Key Players - AudioCure Pharma GmbH , Auris Medical Holding AG, Autifony Therapeutics Ltd, Decibel Therapeutics Ltd 2021/06/22 10:09:00 OpenPR
The Tinnitus Drug Pipeline Market research report is prepared by an in-depth analysis of the present market status and historical data of the Medical Devices industry. The report offers valuable insights by studying the significant market segments such as top
Auris Medical Holding (EARS) Presents At LD Micro Invitational XI Conference - Slideshow 2021/06/11 19:08:10 Seeking Alpha
Auris Medical Holding to Present at LD Micro Invitational XI Conference 2021/05/28 00:00:00 BioSpace
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference
Auris Medical (NASDAQ:EARS) Lowered to Hold at Zacks Investment Research 2020/10/24 11:58:42 Zolmax News
Zacks Investment Research lowered shares of Auris Medical (NASDAQ:EARS) from a buy rating to a hold rating in a report published on Friday morning, Zacks.com reports. According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects […]
11 Healthcare Stocks Moving In Tuesday's Pre-Market Session 2020/10/13 08:24:00 Benzinga
Gainers Auris Medical Holding (NASDAQ:EARS) shares rose 90.63% to $1.61. The market value of their outstanding shares is at $7.6 million. SOS (NYSE:SOS) …
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data 2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval 2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing 2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).